earn increas zolgensma/piqray
follow weekend fda approv zolgensma sma gene
therapi piqray mutant breast cancer revisit
novarti model assumpt increas target price sfr
sfr line revis ep increas near-term
zolgensma estim reflect broader anticip label rais
probabl success broader patient use intrathec dose
note list price per patient much line
net price assumpt note patient treat
medicaid schip program carri mandatori discount
ep increas revisit model assumpt
zolgensma piqray follow fda approv updat model
recent acquisit xiidra also revis sale market
assumpt follow manag commentari last week
manag taken togeth increas ep
increas averag ep
cosentyx entresto novel growth driver off-set midterm gener
eros novarti continu see strong launch momentum cosentyx
entresto zolgensma sma mayzent ms piqray breast
cancer set add growth growth drive posit margin
mix enabl novarti off-set patent expiri next year
potenti upsid depend length gilenya patent extens
howev larg reflect premium valuat view
catalyst risk new product launch momentum data
valuat novarti trade pe premium eu major
peer ex-azn novarti trade ev/npv vs eu peer
valuat metric
price-to-earnings rel local market
number share
price month
price rel chart measur perform
swiss market ind close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price may rate neutral target price analyst matthew weston
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
novarti provid healthcar solut compani
multi-national group compani special research
develop manufactur market rang healthcar
product led pharmaceut
scenario base pipelin success
higher peak sale cosentyx stronger sandoz
biopharma revenu gilenya patent life
extens
grey scenario base pipelin success lower
peak sale entresto lower cosentyx peak sale
lower sandoz growth
price rel chart measur perform swiss market
ind close
spot exchang rate
observ zolgensma approv
note research bulletin friday see breadth
zolgensma label top end market expect cover patient two
year age includ diagnos genet test symptom aris
captur incid preval type sma market proport
symptomat type patient label also captur incid sma
patient born state mandatori test program birth assum
penetr genet test birth increas time
alreadi captur assumpt intrathec administr set
updat zolgensma expect figur
price see list price much line base
case net price assumpt list price adjust deduct
modest rebat payment distribut channel particip provis
note manag commentari yesterday confer call
patient expect fund commerci insur patient
fund medicaid/schip note medicaid mandatori price
discount best-avail price within medicaid program drug approv
sole paediatr indic
novarti offer number pay perform option reimburs
zolgensma us includ spread payment time link
payment on-going patient outcom zolgensma revenu recognit
believ novarti recognis virtual sale time patient
treatment assum compani hold back modest conting liabil
base patient outcom data clinic trial accord
logist administr manag assum take week
diagnosi zolgensma administr includ aav viral test
prescript process via novarti one gene program
formulari access zolgensma novarti anticip contract
coverag requir major commerci payer novarti contract
coverag remaind expect month novarti
anticip medicaid contract take month
follow manag commentari
chang forecast
revisit model assumpt zolgensma piqray follow fda approv
updat model recent acquisit xiidra also revis sale
manag event taken togeth increas ep
increas averag ep
price increas sfr line increas
ep increas target price per share target
price set base assum premium novarti european major
pharma peer pe rel basi histor pe rel premium
last year last month assum pharma sector
trade premium european market pharmavalu equiti
npv sfr per share
figur set chang zolgensma estim increas
probabl type incid sma increas probabl
type preval patient follow fda decis allow
treatment infant year age also bring forward portion
incid revenu reflect approv pre-symptomat patient diagnos
genet test birth assum us birth cover test
today also rais probabl success intrathec dose larger children
type sma
figur credit suiss chang zolgensma expect
piqray alpelisib increas probabl success
also bring forward launch revenu earlier reflect fda approv
earlier expect previou assumpt cs continu forecast
peak sale potenti piqray see drug posit similar manner
afinitor later line er breast cancer time move
adjuv set see market potenti piqray build
add xiidra model follow novarti acquisit product takeda
may assum relaunch product steadi
growth trajectori us canada assum modest sale potenti ex-u
market outsid canada peak sale assumpt mean
novarti trigger addit conting payment due takeda sale
out-performance pharmavalu npv
revisit sale market assumpt
commentari last week manag event assum limit
growth sg current infrastructur absorb launch effort zolgensma
piqray other
charl martineau univers toronto figur chang forecast
fulli dilut share
fulli dilut share
fx impact sale
fx impact op incom
net financ adj alcon/ab
sale
line last year
mid- high singl digit cer
op incom
end
alreadi use
novarti premium/ discount eu
novarti premium/ discount global
note zolgensma manag call
fda approv ahead pdufa date prioriti review
launch immedi product avail ship within next week
fulli prepar readi launch
genet diagnosi sma
year age
regardless copi number
symptomat pre-symptomat
requir initi monitor
prior treatment
assess liver function clinician lab test acut liver injuri possibl
therapi
baselin platelet troponin-i
start steroid cours day prior treatment
continu steroid treatment least month
assess liver function month
taper steroid liver function return normal day
assess platelet troponin-i month
dose increment come kit vial
patient yr age use multipl pack
kit made illinoi ship dri ice gps-track exclus courier partner
year
instal year
ultra-rar cost-effect threshold
cost spinraza
genet paediatr ultra-orphan treatment
strong indic marketplac readi
specialist physician identifi patient test day turnaround send rx
onegen patient support program
onegen program coordin financi support elig patient schedul
shipment therapi courier test test order
payer approv prior author notifi physician payer advanc
discuss term
institut administ therapi patient institut readi far
administ therapi contract turnaround less equal day
aim treatment within week diagnosi
illinoi primari site commerci product
acceler releas protocol agre fda
site develop north carolina colorado also third parti
potenti patient us launch
patient preval popul may spinraza vs cs assumpt
might opportun switch preval patient popul
equival newli diagnos per month
 payer respond label
indic copi miss gene regardless copi number
determin type smn therefor sma patient year age includ
 insur coverag previous said coverag day
remaind patient
dont anticip need contract busi cover request zolgensma
ensur good uptak payer remaind coverag develop next
month medicaid like month take bit longer
 timelin intrathec earlier
continu dialogu fda updat
 capac accommod switch preval pop demand aris
enough treat elig popul next year confid
 split commerci vs medicaid
 preval popul might peopl switch anoth therapi
one time treatment attract dissatisfact current therapi
opportun gain new outcom child
patient came pre-exist therapi switch payer
reluct extent look unlik allow use drug time
 instal plan work patient chang lose insur coverag
plan individu payer portabl plan current origin payer would
alway respons
 outcomes-bas patient plan ident
individu payer basic structur look year outcom use hard
endpoint death perman ventil
 manufactur capac approv geographi still manufactur
anticip eu japan approv later year still confid suppli
 outcome-bas agreement book revenu up-front
would recognis almost revenu up-front soon patient dose
 label flexibl year old
pack patient weight novarti work individu
patient enabl therapi
patient receiv prior therapi move onto zolgensma payer
impact switch
fulli readi test ship etc test everi step system fulli
readi launch
 cash-flow recognit book year period
amortis year plan choos take instal plan
 mani spinraza patient queue
patient map treat date
 type diagnos pre-symptomat
state screen regularli sma identifi famili histori expect
rise next month type diagnos year old
symptom type pick year age symptomat much
 preval patient proport spinraza
patient like benefit see neuron would better preserv
mani previous opportun switch patient base
primarili parent choic
 market access program safeti patient greater month old concern
liver injuri
dose consist across patient rel weight lft differ base
size patient dont anticip addit risk higher weight seen
expect bare durat time market
 durat payment step certain point due patent expiri
get back
 revenu recognit recognis major net sale up-front would also trigger
entireti royal burden up-front
revenu recognis up-front get back royalti
 patent portfolio acquir avx parti get
patent term extens dictat market authoris holder novarti control
note piqray manag call
first target therapi ever approv treatment metastat breast cancer
approv combin fulvestr post-menopaus women men
approv allow use therapi
advanc breast cancer patient may wors prognosi
due mutat
first new drug approv fda oncolog center excel real-tim
approv diagnost test
us suppli readi commerci sale
agreement foundat medicin develop plasma tissu test
engag payer cover target popul us
investig driven cancer solid tumour
 piqray manag toler dropout treat dose intens clinic
trial guid physician treatment alter make toler
observ target hypoglycaemia edit protocol usual identifi
week usag hypoglycaemia place metformin normalis
hypoglycaemia return piqray think hypoglycaemia well manag
uniqu option patient pik mutat metastat breast cancer
 piqray vs inhibitor come first
label allow subset trial expect piqray
initi time want gener data justifi earlier line treatment
basic number share
fulli dilut number share
compani mention price
